Research Progress of Resistance Genes and Targeted Therapy for Gallbladder Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YU Yuanlin ^1,2 , JIANG Bojian ¹ ,  YU Jiwei. ¹

1.The First Department of General Surgery， Affiliated No.3 People’s Hospital， Shanghai Jiao Tong University School of Medicine， Shanghai 201999， China;;
2.Graduate School， Bengbu Medical College， Bengbu 233030， Anhui Province， China;

Corresponding?author：

YU Jiwei., Email: jiweiyu919@hotmail.com

Keywords：

Gallbladder carcinoma; Resistance gene; Targeted therapy

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To summarize the development of gallbladder carcinoma related resistance genes and targeted therapy.
Methods 　Domestic and international publications online involving resistance genes and targeted therapy of gallbladder carcinoma in recent years were collected and reviewed.
Results 　Recent studies had shown that chemotherapy drug resistance of gallbladder carcinoma mainly involved lysosome protein transmembrane β4 （LAPTM4B） gene， NF-E2-related factor 2 （Nrf2） gene， and cancer stem cells （CSCs）. While the latest gene targets of treatment for gallbladder carcinoma mainly involved LAPTM4B， Nemo-like kinase （NLK）， tissue factor way inhibitor-2 （TFPI-2）， vascular endothelial growth factor-D （VEGF-D）， epidermal growth factor receptor （EGFR）， and melanoma differentiation-associated gene 7/interleukin 24 （mda-7/IL-24） gene.
Conclusion 　The research involving resistance genes and targeted therapy of gallbladder carcinoma has make a certain progress， which broaden the concept of traditional treatment of gallbladder carcinoma.

Citation： YU Yuanlin,JIANG Bojian,YU Jiwei.. Research Progress of Resistance Genes and Targeted Therapy for Gallbladder Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(12): 1432-1436. doi: Copy

1.	Kokudo N， Makuuchi M， Natori T， et al. Strategies for surgical treatment of gallbladder carcinoma based on information available before resection[J]. Arch Surg， 2003， 138(7)：741-750.
2.	Goldin RD， Roa JC. Gallbladder cancer：a morphological and molecular update[J]. Histopathology， 2009， 55(2)：218-229.
3.	Rai R， Tewari M， Kumar M， et al. p53：its alteration and gallbladder cancer[J]. Eur J Cancer Prev， 2011， 20(2)：77-85.
4.	Alsheyab FM， Ziadeh MT， Bani-Hani KE. Expression of p21 and p27 in gallbladder cancer[J]. Saudi Med J， 2007， 28(5)：683-687.
5.	Moon WS， Park HS， Lee H， et al. Co-expression of cox-2， C-metand beta-catenin in cells forming invasive front of gallbladder cancer[J]. Cancer Res Treat， 2005， 37(3)：171-176.
6.	Kim YW， Huh SH， Park YK， et al. Expression of the c-erb-B2and p53 protein in gallbladder carcinomas[J]. Oncol Rep， 2001， 8(5)：1127-1132.
7.	Rupesh P， Manoj P， Vijay Kumar S. Biomarkers in carcinoma of the gallbladder[J]. Expert Opin Med Diagn， 2008， 2(5)：511-526.
8.	Boutros C， Gary M， Baldwin K， et al. Gallbladder cancer：past， present and an uncertain future[J]. Surg Oncol， 2012， 21(4)：183-191.
9.	Andrén-Sandberg A. Molecular biology of gallbladder cancer：potential clinical implications[J]. N Am J Med Sci， 2012， 4(10)：435-441.
10.	Zhai G， Yan K， Ji X， et al. LAPTM4B allele*2 is a marker of poor prognosis for gallbladder carcinoma[J]. PLoS One， 2012， 7(9)：e45290.
11.	Meng F， Li H， Zhou R， et al. LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis[J]. Biomarkers， 2013， 18(2)：136-143.
12.	Meng FL， Song HT， Luo C， et al. Correlation of LAPTM4B polymorphisms with cervical carcinoma[J]. Cancer， 2011， 117(12)：2652-2658.
13.	Zhou L， He XD， Yu JC， et al. Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells[J]. Surgery， 2011， 150(1)：25-31.
14.	Lau A， Villeneuve NF， Sun Z， et al. Dual roles of Nrf2 in cancer[J]. Pharmacol Res， 2008， 58(5-6)：262-270.
15.	Zhang L， Wang N， Zhou S， et al. Propofol induces proliferationand invasion of gallbladder cancer cells through activation of Nrf2[J]. J Exp Clin Cancer Res， 2012， 31(1)：66-74.
16.	Shibata T， Kokubu A， Gotoh M， et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer[J]. Gastroenterology， 2008， 135(4)：1358-1368.
17.	Wang J， Zhang M， Zhang L， et al. Correlation of Nrf2， HO-1， and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival[J]. J Surg Res， 2010， 164(1)：e99-e105.
18.	Bonnet D， Dick JE. Human acute myeloid leukemia is organizedas a hierarchy that originates from a primitive hematopoietic cell[J]. Nat Med， 1997， 3(7)：730-737.
19.	張鵬，俞繼衛，姜波健. 腫瘤干細胞與胃腸道癌發生和轉移[J].中國普外基礎與臨床雜志， 2009， 16(1)：81-84.
20.	Bomken S， Fiser K， Heidenreich O， et al. Understanding the cancer stem cell[J]. Br J Cancer， 2010， 103(4)：439-445.
21.	陸瑞祺，吳巨鋼，周國才，等. 胃癌CD133陽性細胞的純化及其生物學特性研究[J]. 中國普外基礎與臨床雜志， 2011， 18(12)：1265-1270.
22.	Zhang Z， Zhu F， Xiao L， et al. Side population cells in human gallbladder cancer cell line GBC-SD regulated by TGF-β-induced epithelial-mesenchymal transition[J]. J Huazhong Univ Sci Technolog Med Sci， 2011， 31(6)：749-755.
23.	胡均，李健，劉文松，等. 人膽囊癌GBC-SD細胞系中干細胞樣SP細胞群的分離及其ABCG2的表達[J]. 華中科技大學學報：醫學版， 2008， 37(2)：200-203.
24.	Shi C， Tian R， Wang M， et al. CD44＋ CD133＋ population exhi-bits cancer stem cell-like characteristics in human gallbladder carc-inoma[J]. Cancer Biol Ther， 2010， 10(11)：1182-1190.
25.	Sachlos E， Risueño RM， Laronde S， et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells[J]. Cell， 2012， 149(6)：1284-1297.
26.	Maugeri-Saccà M， Vigneri P， De Maria R. Cancer stem cells and chemosensitivity[J]. Clin Cancer Res， 2011， 17(15)：4942-4947.
27.	Li XX， Wang J， Wang HL， et al. Characterization of cancer ste-mlike cells derived from a side population of a human gallbladder carcinoma cell line， SGC-996[J]. Biochem Biophys Res Commun， 2012， 419(4)：728-734.
28.	Yang H， Zhai G， Ji X， et al. Correlation of LAPTM4B polymorp-hisms with gallbladder carcinoma susceptibility in Chinese patients[J]. Med Oncol， 2012， 29(4)：2809-2813.
29.	Yasuda J， Tsuchiya A， Yamada T， et al. Nemo-like kinase inducesapoptosis in DLD-1 human colon cancer cells[J]. Biochem Biop-hys Res Commun， 2003， 308(2)：227-233.
30.	Jung KH， Kim JK， Noh JH， et al. Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma[J]. J Cell Biochem， 2010， 110(3)：687-696.
31.	Tan Z， Li M， Wu W， et al. NLK is a key regulator of proliferationand migration in gallbladder carcinoma cells[J]. Mol Cell Biochem， 2012， 369(1-2)：27-33.
32.	Qin Y， Zhang S， Gong W， et al. Adenovirus-mediated gene transfer of tissue factor pathway inhibitor-2 inhibits gallbladder carcinoma growth in vitro and in vivo[J]. Cancer Sci， 2012， 103(4)：723-730.
33.	蔣雷，陳燕凌，余菲菲，等. 膽囊癌組織中血管內皮生長因子C和D的表達及其與淋巴管和血管生成的關系[J]. 中華腫瘤雜志， 2010， 32(3)：190-195.
34.	Lin W， Jiang L， Chen Y， et al. Vascular endothelial growth factor-D promotes growth， lymphangiogenesis and lymphatic metastasis in gallbladder cancer[J]. Cancer Lett， 2012， 314(2)：127-136.
35.	Pignochino Y， Sarotto I， Peraldo-Neia C， et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabinein biliary tract and gallbladder carcinomas[J]. BMC Cancer， 2010，10(1)：631.
36.	Jia J， Li S， Gong W， et al. mda-7/IL-24 induces apoptosis in human GBC-SD gallbladder carcinoma cells via mitochondrial apoptotic pathway[J]. Oncol Rep， 2011， 25(1)：195-201.
37.	Zhang JT， Fan YZ， Chen CQ， et al. Norcantharidin：a potentialantiangiogenic agent for gallbladder cancers in vitro and in vivo[J].Int J Oncol， 2012， 40(5)：1501-1514.
38.	秦一雨，李濟宇，李松崗，等. 生長抑素逆轉膽囊癌細胞株耐藥性的作用研究[J]. 中華外科雜志， 2008， 46(5)：381-383.
39.	Wang JW， Peng SY， Li JT， et al. Identification of metastasis-ass-ociated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1[J]. Cancer Lett， 2009， 281(1)：71-81.
40.	Zhang Z， Wang X， Wu W， et al. Effects of matrine on proliferation and apoptosis in gallbladder carcinoma cells (GBC-SD)[J]. Phytother Res， 2012， 26(6)：932-937.

1. Kokudo N， Makuuchi M， Natori T， et al. Strategies for surgical treatment of gallbladder carcinoma based on information available before resection[J]. Arch Surg， 2003， 138(7)：741-750.
2. Goldin RD， Roa JC. Gallbladder cancer：a morphological and molecular update[J]. Histopathology， 2009， 55(2)：218-229.
3. Rai R， Tewari M， Kumar M， et al. p53：its alteration and gallbladder cancer[J]. Eur J Cancer Prev， 2011， 20(2)：77-85.
4. Alsheyab FM， Ziadeh MT， Bani-Hani KE. Expression of p21 and p27 in gallbladder cancer[J]. Saudi Med J， 2007， 28(5)：683-687.
5. Moon WS， Park HS， Lee H， et al. Co-expression of cox-2， C-metand beta-catenin in cells forming invasive front of gallbladder cancer[J]. Cancer Res Treat， 2005， 37(3)：171-176.
6. Kim YW， Huh SH， Park YK， et al. Expression of the c-erb-B2and p53 protein in gallbladder carcinomas[J]. Oncol Rep， 2001， 8(5)：1127-1132.
7. Rupesh P， Manoj P， Vijay Kumar S. Biomarkers in carcinoma of the gallbladder[J]. Expert Opin Med Diagn， 2008， 2(5)：511-526.
8. Boutros C， Gary M， Baldwin K， et al. Gallbladder cancer：past， present and an uncertain future[J]. Surg Oncol， 2012， 21(4)：183-191.
9. Andrén-Sandberg A. Molecular biology of gallbladder cancer：potential clinical implications[J]. N Am J Med Sci， 2012， 4(10)：435-441.
10. Zhai G， Yan K， Ji X， et al. LAPTM4B allele*2 is a marker of poor prognosis for gallbladder carcinoma[J]. PLoS One， 2012， 7(9)：e45290.
11. Meng F， Li H， Zhou R， et al. LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis[J]. Biomarkers， 2013， 18(2)：136-143.
12. Meng FL， Song HT， Luo C， et al. Correlation of LAPTM4B polymorphisms with cervical carcinoma[J]. Cancer， 2011， 117(12)：2652-2658.
13. Zhou L， He XD， Yu JC， et al. Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells[J]. Surgery， 2011， 150(1)：25-31.
14. Lau A， Villeneuve NF， Sun Z， et al. Dual roles of Nrf2 in cancer[J]. Pharmacol Res， 2008， 58(5-6)：262-270.
15. Zhang L， Wang N， Zhou S， et al. Propofol induces proliferationand invasion of gallbladder cancer cells through activation of Nrf2[J]. J Exp Clin Cancer Res， 2012， 31(1)：66-74.
16. Shibata T， Kokubu A， Gotoh M， et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer[J]. Gastroenterology， 2008， 135(4)：1358-1368.
17. Wang J， Zhang M， Zhang L， et al. Correlation of Nrf2， HO-1， and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival[J]. J Surg Res， 2010， 164(1)：e99-e105.
18. Bonnet D， Dick JE. Human acute myeloid leukemia is organizedas a hierarchy that originates from a primitive hematopoietic cell[J]. Nat Med， 1997， 3(7)：730-737.
19. 張鵬，俞繼衛，姜波健. 腫瘤干細胞與胃腸道癌發生和轉移[J].中國普外基礎與臨床雜志， 2009， 16(1)：81-84.
20. Bomken S， Fiser K， Heidenreich O， et al. Understanding the cancer stem cell[J]. Br J Cancer， 2010， 103(4)：439-445.
21. 陸瑞祺，吳巨鋼，周國才，等. 胃癌CD133陽性細胞的純化及其生物學特性研究[J]. 中國普外基礎與臨床雜志， 2011， 18(12)：1265-1270.
22. Zhang Z， Zhu F， Xiao L， et al. Side population cells in human gallbladder cancer cell line GBC-SD regulated by TGF-β-induced epithelial-mesenchymal transition[J]. J Huazhong Univ Sci Technolog Med Sci， 2011， 31(6)：749-755.
23. 胡均，李健，劉文松，等. 人膽囊癌GBC-SD細胞系中干細胞樣SP細胞群的分離及其ABCG2的表達[J]. 華中科技大學學報：醫學版， 2008， 37(2)：200-203.
24. Shi C， Tian R， Wang M， et al. CD44＋ CD133＋ population exhi-bits cancer stem cell-like characteristics in human gallbladder carc-inoma[J]. Cancer Biol Ther， 2010， 10(11)：1182-1190.
25. Sachlos E， Risueño RM， Laronde S， et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells[J]. Cell， 2012， 149(6)：1284-1297.
26. Maugeri-Saccà M， Vigneri P， De Maria R. Cancer stem cells and chemosensitivity[J]. Clin Cancer Res， 2011， 17(15)：4942-4947.
27. Li XX， Wang J， Wang HL， et al. Characterization of cancer ste-mlike cells derived from a side population of a human gallbladder carcinoma cell line， SGC-996[J]. Biochem Biophys Res Commun， 2012， 419(4)：728-734.
28. Yang H， Zhai G， Ji X， et al. Correlation of LAPTM4B polymorp-hisms with gallbladder carcinoma susceptibility in Chinese patients[J]. Med Oncol， 2012， 29(4)：2809-2813.
29. Yasuda J， Tsuchiya A， Yamada T， et al. Nemo-like kinase inducesapoptosis in DLD-1 human colon cancer cells[J]. Biochem Biop-hys Res Commun， 2003， 308(2)：227-233.
30. Jung KH， Kim JK， Noh JH， et al. Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma[J]. J Cell Biochem， 2010， 110(3)：687-696.
31. Tan Z， Li M， Wu W， et al. NLK is a key regulator of proliferationand migration in gallbladder carcinoma cells[J]. Mol Cell Biochem， 2012， 369(1-2)：27-33.
32. Qin Y， Zhang S， Gong W， et al. Adenovirus-mediated gene transfer of tissue factor pathway inhibitor-2 inhibits gallbladder carcinoma growth in vitro and in vivo[J]. Cancer Sci， 2012， 103(4)：723-730.
33. 蔣雷，陳燕凌，余菲菲，等. 膽囊癌組織中血管內皮生長因子C和D的表達及其與淋巴管和血管生成的關系[J]. 中華腫瘤雜志， 2010， 32(3)：190-195.
34. Lin W， Jiang L， Chen Y， et al. Vascular endothelial growth factor-D promotes growth， lymphangiogenesis and lymphatic metastasis in gallbladder cancer[J]. Cancer Lett， 2012， 314(2)：127-136.
35. Pignochino Y， Sarotto I， Peraldo-Neia C， et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabinein biliary tract and gallbladder carcinomas[J]. BMC Cancer， 2010，10(1)：631.
36. Jia J， Li S， Gong W， et al. mda-7/IL-24 induces apoptosis in human GBC-SD gallbladder carcinoma cells via mitochondrial apoptotic pathway[J]. Oncol Rep， 2011， 25(1)：195-201.
37. Zhang JT， Fan YZ， Chen CQ， et al. Norcantharidin：a potentialantiangiogenic agent for gallbladder cancers in vitro and in vivo[J].Int J Oncol， 2012， 40(5)：1501-1514.
38. 秦一雨，李濟宇，李松崗，等. 生長抑素逆轉膽囊癌細胞株耐藥性的作用研究[J]. 中華外科雜志， 2008， 46(5)：381-383.
39. Wang JW， Peng SY， Li JT， et al. Identification of metastasis-ass-ociated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1[J]. Cancer Lett， 2009， 281(1)：71-81.
40. Zhang Z， Wang X， Wu W， et al. Effects of matrine on proliferation and apoptosis in gallbladder carcinoma cells (GBC-SD)[J]. Phytother Res， 2012， 26(6)：932-937.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Resistance Genes and Targeted Therapy for Gallbladder Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content